Hydrophobic interactions between the HA helix and S4-S5 linker modulate apparent Ca


Journal

Acta physiologica (Oxford, England)
ISSN: 1748-1716
Titre abrégé: Acta Physiol (Oxf)
Pays: England
ID NLM: 101262545

Informations de publication

Date de publication:
01 2021
Historique:
received: 01 06 2020
revised: 09 08 2020
accepted: 20 08 2020
pubmed: 1 9 2020
medline: 19 8 2021
entrez: 1 9 2020
Statut: ppublish

Résumé

Small-conductance Ca Site-directed mutagenesis, electrophysiological recordings and molecular dynamic (MD) simulations were utilized. Mutations that decrease hydrophobicity at the HA-S4-S5 interface lead to Ca The electrophysiological data and MD simulations collectively suggest a crucial role of the interactions between the HA helix and S4-S5 linker in the apparent Ca

Identifiants

pubmed: 32865319
doi: 10.1111/apha.13552
pmc: PMC7736289
mid: NIHMS1626265
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13552

Subventions

Organisme : NINDS NIH HHS
ID : R21 NS101182
Pays : United States
Organisme : NINDS NIH HHS
ID : R33 NS101182
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd.

Références

Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4828-33
pubmed: 23487779
Nat Neurosci. 2006 Mar;9(3):389-97
pubmed: 16474392
Nat Chem Biol. 2014 Sep;10(9):753-9
pubmed: 25108821
Neuron. 2004 Sep 16;43(6):847-58
pubmed: 15363395
J Neurosci. 2010 May 26;30(21):7249-57
pubmed: 20505091
Biochim Biophys Acta. 2001 Mar 19;1518(1-2):36-46
pubmed: 11267657
Br J Pharmacol. 2013 Sep;170(2):293-303
pubmed: 23734697
Neurobiol Dis. 2014 Jul;67:140-8
pubmed: 24727095
Nature. 2001 Apr 26;410(6832):1120-4
pubmed: 11323678
Am J Hum Genet. 2019 Jun 6;104(6):1139-1157
pubmed: 31155282
Br J Pharmacol. 2017 Dec;174(23):4396-4408
pubmed: 28925012
J Chem Theory Comput. 2008 Mar;4(3):435-47
pubmed: 26620784
Front Pharmacol. 2020 Feb 28;11:159
pubmed: 32180722
J Neurosci. 2012 Oct 31;32(44):15533-46
pubmed: 23115190
J Neurosci. 2010 May 26;30(21):7258-68
pubmed: 20505092
J Neurophysiol. 2016 Jun 1;115(6):2840-51
pubmed: 26984424
Cell. 2007 Dec 14;131(6):1047-58
pubmed: 18083096
Blood. 2015 Sep 10;126(11):1273-80
pubmed: 26148990
Neurology. 2010 Mar 9;74(10):839-45
pubmed: 20211908
J Membr Biol. 1995 Jul;146(2):123-32
pubmed: 7473683
Stroke. 2005 Jul;36(7):1526-32
pubmed: 15933259
Vascul Pharmacol. 2016 Apr;79:24-31
pubmed: 26239885
Mol Pharmacol. 2006 Nov;70(5):1771-82
pubmed: 16926279
Am J Physiol. 1996 Nov;271(5 Pt 1):L775-84
pubmed: 8944721
J Gen Physiol. 2009 Oct;134(4):281-93
pubmed: 19752189
Sci Rep. 2018 Jul 16;8(1):10749
pubmed: 30013223
J Neurosci. 2011 Sep 7;31(36):13002-14
pubmed: 21900579
Science. 2018 May 4;360(6388):508-513
pubmed: 29724949
Nat Commun. 2012;3:1021
pubmed: 22929778
J Neurosci. 2007 Feb 28;27(9):2369-76
pubmed: 17329434
Structure. 2012 May 9;20(5):911-23
pubmed: 22579256
Cell Mol Life Sci. 2008 Oct;65(20):3196-217
pubmed: 18597044
Front Pharmacol. 2019 Sep 20;10:972
pubmed: 31616290
Brain Res. 2017 Dec 1;1676:38-45
pubmed: 28917524
Mol Pharmacol. 2009 Feb;75(2):281-95
pubmed: 18955585
Lancet Neurol. 2015 Oct;14(10):985-91
pubmed: 26321318
Nature. 1998 Oct 1;395(6701):503-7
pubmed: 9774106
J Neurosci. 2013 Apr 10;33(15):6557-62
pubmed: 23575853
Eur J Pharmacol. 2018 Jul 15;831:60-67
pubmed: 29753043
Expert Opin Ther Targets. 2010 Feb;14(2):143-55
pubmed: 20055714
Annu Rev Physiol. 2012;74:245-69
pubmed: 21942705
Stroke. 2006 May;37(5):1277-82
pubmed: 16556879
Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1590-9
pubmed: 12805022
Br J Pharmacol. 2007 Jul;151(5):655-65
pubmed: 17486140
PLoS Genet. 2010 Oct 28;6(10):e1001172
pubmed: 21124729
Nat Rev Neurosci. 2004 Oct;5(10):758-70
pubmed: 15378036
J Biol Chem. 2001 Mar 30;276(13):9762-9
pubmed: 11134030
Chem Biol. 2012 Oct 26;19(10):1340-53
pubmed: 23102227
Neurosci Bull. 2010 Jun;26(3):265-71
pubmed: 20502506

Auteurs

Young-Woo Nam (YW)

Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, USA.

Meng Cui (M)

Department of Pharmaceutical Sciences, Northeastern University School of Pharmacy, Boston, MA, USA.

Razan Orfali (R)

Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, USA.

Adam Viegas (A)

Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, USA.

Misa Nguyen (M)

Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, USA.

Eman H M Mohammed (EHM)

Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, USA.

Khalid A Zoghebi (KA)

Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, USA.

Simin Rahighi (S)

Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, USA.

Keykavous Parang (K)

Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, USA.

Miao Zhang (M)

Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, USA.

Articles similaires

T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis

Prevalence and implications of fragile X premutation screening in Thailand.

Areerat Hnoonual, Sunita Kaewfai, Chanin Limwongse et al.
1.00
Humans Fragile X Mental Retardation Protein Thailand Male Female
Humans Receptors, Antigen, T-Cell Proto-Oncogene Proteins p21(ras) Pancreatic Neoplasms T-Lymphocytes

Classifications MeSH